Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome.
Francesca PalandriMassimo BrecciaCamilla MazzoniGiuseppe AuteriElena Maria ElliMalgorzata M TrawinskaNicola PolverelliMario TiribelliGiulia BenevoloAlessandra IurloAlessia TieghiFlorian H HeidelGiovanni CaocciEloise BeggiatoGianni BinottoFrancesco CavazziniMaurizio MiglinoCostanza BosiMonica CrugnolaMonica BocchiaBruno MartinoNovella PuglieseMattia BiondoMarta VenturiLuigi ScaffidiAlessandro IsidoriDaniele CattaneoMauro KramperaFabrizio PaneDaniela CilloniGianpietro SemenzatoRoberto M LemoliAntonio CuneoElisabetta AbruzzeseDaniela BartolettiSimona PagliaNicola VianelliMichele CavoMassimiliano BonifacioGiuseppe A PalumboPublished in: Cancer (2023)
Cytopenic MF has a lower probability of therapeutic success with ruxolitinib as monotherapy and worse outcome. These patients should be considered for alternative therapeutic strategies.